VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | CAR-T cell therapy DLBCL landscape

Ulrich Jäger • 12 Jun 2020
EHA 2020
Diffuse Large B-Cell Lymphoma Lymphoma Antibodies AUTO3 CAR-T Ibrutinib Pembrolizumab

Ulrich Jäger, MD, of the Medical University of Vienna, Vienna, Austria, discusses the current state of the art and future directions of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL) and novel data presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Managing CD30+ CTCL - UK Patient Experience

More from Ulrich Jäger

2:49
Diffuse large B-cell lymphoma lymphoma: Finding the best partner for durvalumab
Ulrich Jäger • 14 Jun 2017
1:34
Recent and upcoming data on axi-cel for patients with NHL
Ulrich Jäger • 18 Jun 2021
2:00
The SADAL study: selinexor for R/R DLBCL
Ulrich Jäger • 17 Dec 2020
3:46
JULIET trial update: Myc expression and T-cell responses in R/R DLBCL
Ulrich Jäger • 17 Dec 2020

Related Videos

1:31
COSTEM 2021: highlights from day one
Arnon Nagler • 21 Oct 2021
2:30
CAR-T updates at COSTEM 2021
Arnon Nagler • 21 Oct 2021
0:41
Recent advances in understanding and managing CTCL
Robert Knobler • 15 Oct 2021
1:05
Extracorporeal photopheresis for the treatment of CTCL
Robert Knobler • 15 Oct 2021
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals